rs5015480 — HHEX HHEX/IDE locus variant

HHEX/IDE — The Beta-Cell Blueprint Variant

When scientists began systematically scanning the human genome for type 2 diabetes risk, one of the first and most consistently replicated signals landed on chromosome 10q23 — near two genes with seemingly different jobs: HHEX¹¹ HHEX
Hematopoietically Expressed Homeobox — a transcription factor that acts as a master switch for organ development, including the pancreas and IDE²² IDE
Insulin-Degrading Enzyme — a metalloprotease that degrades insulin and amyloid beta peptides. The SNP rs5015480 sits in this locus and is in complete linkage disequilibrium (r² = 1) with the primary association marker rs1111875, meaning the two variants are inherited together as a single functional unit in nearly all human populations.

The Mechanism

HHEX encodes a homeodomain transcription factor expressed in the liver, thyroid, and — critically — the developing pancreas. During embryogenesis, HHEX is required for proper formation of the ventral pancreatic bud; mice with HHEX knockout fail to develop a normal pancreas and show profound defects in insulin-producing beta-cell mass. In adult beta cells, HHEX continues to regulate genes involved in beta-cell identity and function, including insulin gene expression programs.

The C allele at rs5015480 (and the linked C allele at rs1111875) is associated with reduced HHEX expression in pancreatic tissue, which translates into diminished beta-cell function and reduced first-phase insulin secretion in response to glucose. IDE, located nearby, degrades secreted insulin — variants that alter IDE expression or activity could further modulate circulating insulin levels, though whether IDE or HHEX is the causal gene remains an active area of investigation.

The Evidence

This locus was identified simultaneously by multiple landmark GWAS in 2007, cementing its status as one of the most robustly replicated T2D signals in the literature.

The Sladek et al. 2007 GWAS³³ Sladek et al. 2007 GWAS
Sladek R et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature, 2007 tested 392,935 SNPs in a French case-control cohort and identified the IDE-KIF11-HHEX locus as one of four novel T2D risk regions, together with TCF7L2 replication.

The Scott et al. 2007 FUSION study⁴⁴ Scott et al. 2007 FUSION study
Scott LJ et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science, 2007 confirmed HHEX among validated T2D susceptibility loci. Combined analysis across the FUSION, DGI, and WTCCC/UKT2D cohorts yielded an odds ratio of 1.13 (95% CI 1.09–1.17)⁵⁵ 1.13 (95% CI 1.09–1.17)
Scott LJ et al. Science, 2007 per C allele (p = 5.7 × 10⁻¹⁰), with a risk allele frequency of ~0.52 in controls. The effect is modest but genome-wide significant and highly reproducible across European, East Asian, and other populations.

Zeggini et al. 2008⁶⁶ Zeggini et al. 2008
Zeggini E et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet, 2008 placed HHEX/IDE among 10 established T2D loci, each conferring allelic odds ratios in the 1.1–1.2 range.

Takeuchi et al. 2009⁷⁷ Takeuchi et al. 2009
Takeuchi F et al. Confirmation of multiple risk loci and genetic impacts by a genome-wide association study of type 2 diabetes in the Japanese population. Diabetes, 2009 confirmed the HHEX association in a Japanese cohort, demonstrating the cross-ethnic stability of this signal. Notably, the T allele (the protective variant) is far more common in East Asian populations (~82% frequency vs ~42% in Europeans), which may partly explain differences in T2D genetic architecture across ancestries.

Practical Implications

The HHEX/IDE locus acts primarily through the insulin secretion axis — specifically impaired beta-cell development and reduced first-phase insulin release. Unlike variants that primarily affect insulin resistance (PPARG, ADIPOQ), HHEX risk carriers have beta cells that are constitutively less efficient at responding to a glucose load.

The single most actionable implication is protecting beta-cell reserve through dietary patterns that minimize demand on the insulin secretory apparatus. This means limiting glycemic spikes — not through generic "healthy eating" but through specifically timed, lower-glycemic-index meal patterns that match the reduced first-phase insulin capacity of HHEX C-allele carriers.

Post-meal glucose monitoring and periodic HbA1c checks are particularly informative for this genotype, because the impaired first-phase insulin response is precisely what blunts early post-meal glucose suppression and progressively loads beta-cell reserve over decades.

Interactions

HHEX rs5015480 operates through the insulin secretion pathway, distinct from the insulin resistance pathway. Carrying risk alleles at both this locus (impaired secretion) and at TCF7L2 rs7903146 (impaired Wnt-mediated beta-cell function) compounds T2D risk through converging but independent mechanisms. Similarly, co-inheritance with SLC30A8 rs13266634 (zinc transporter affecting insulin granule crystallization) further loads the insulin secretion pathway. Individuals with risk alleles at multiple secretion- pathway loci should give highest priority to metabolic monitoring and glycemic-load management.